Catalog No.
DHB94403
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
TNF, Tumor necrosis factor ligand superfamily member 2, N-terminal fragment, ICD2, NTF, TNF-a, TNF-alpha, Tumor necrosis factor, TNFSF2, TNFA, Cachectin, ICD1
Concentration
1.2 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01375
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
TA-650, cA2, CAS: 170277-31-3
Clone ID
Infliximab
Magnetic resonance spectroscopy biomarkers of anti-inflammatory interventions in mood disorders: A systematic review of clinical trials., PMID:40505984
Effectiveness and Safety of Advanced Dual-Targeted Therapy in Refractory Perianal Crohn's Disease., PMID:40504122
Post-traumatic ileal stenosis: a rare entity not to be confused with Crohn's disease., PMID:40503976
Curcumin-QingDai Combination as Treatment for Crohn's Disease: A Case Report., PMID:40503450
Serial 18F-Fluorodeoxyglucose Positron Emission Tomography to Assess the Efficacy of Infliximab in Steroid Refractory Cardiac Sarcoidosis., PMID:40499889
Comparative effectiveness of ustekinumab versus infliximab in the management of perianal fistulizing Crohn's disease: a retrospective study in China., PMID:40499579
Which first? Surgery or biologic therapy for ileocolic Crohn's disease in the real world., PMID:40498697
The Use of Intravenous Infliximab to Treat Cancer Related Fistulae: A Case Report in Home-Based Palliative Care Improving Quality of Life and Closure., PMID:40498467
Upadacitinib for refractory Behçet's disease with myelodysplastic syndrome and trisomy 8/9: a case report and mechanistic insights., PMID:40496858
Clinical characteristics and treatment of infantile Takayasu arteritis in the Chinese Han population: a single-center study., PMID:40495185
Development of thymoma without myasthenia gravis in a patient with radiographic axial spondyloarthritis treated with tumor necrosis factor-α inhibitors., PMID:40491307
Bibliometric analysis of global research trends on ultrasound in inflammatory bowel disease: A quickly developing field., PMID:40489862
Metabolism and Response to Stress Gene Signatures Reveal Ulcerative Colitis Heterogeneity and Identify Patients With Increased Response to Therapy., PMID:40488582
Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients with COVID-19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV-1 IM)., PMID:40488513
Efficacy and Safety of Vedolizumab with Glucocorticoids vs Infliximabin Severe Ulcerative Colitis: A Retrospective Study., PMID:40487981
Drug survival, long-term safety and efficacy of anti-TNF-alpha biosimilars: a monocentric retrospective study., PMID:40485573
Clinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India., PMID:40485102
Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction., PMID:40484132
Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data., PMID:40481399
Tumor necrosis factor α inhibitor-induced alopecia in pediatric patients: a cohort of 20 patients and review of the literature., PMID:40481366
Anti-tumor Necrosis Factor-Alpha (TNF-α)-Induced Hypertrophic Lichen Planus: A Case Report., PMID:40470457
Pharmacogenomics of TNF inhibitors., PMID:40469293
Infliximab-Induced Immune Thrombocytopenic Purpura in an Ulcerative Colitis Patient., PMID:40469247
Comment on a Risk Stratification Tool for Relapse After Intravenous-to-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases., PMID:40464796
Machine Learning Modeling for Predicting Infliximab Pharmacokinetics in Pediatric and Young Adult Patients With Crohn Disease: Leveraging Ensemble Modeling With Synthetic and Real-World Data., PMID:40459932
Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission., PMID:40454138
Higher induction and maintenance infliximab trough levels are associated with radiological perianal fistula healing in pediatric patients with Crohn's disease., PMID:40453222
Treatment of Autoimmune Enteropathy With Vedolizumab., PMID:40452653
Peripheral neuropathies associated with anti-tnf-α treatments: a systematic review and proposed recommendations., PMID:40447953
JAK-STAT inhibitors in noninfectious uveitis - A review., PMID:40434456
Optimizing Biologic Therapy for the Prevention of Post-Operative Recurrence in Crohn's Disease: Current Evidence and Future Perspectives., PMID:40427059
The Effects of the Biological Agents Infliximab, Vedolizumab, and Ustekinumab on Intestinal Anastomosis: An Experimental Study in Rats., PMID:40426907
Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System., PMID:40426835
Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis., PMID:40421460
Efficacy and safety of dual-targeted therapy for refractory inflammatory bowel disease: a retrospective case series from three tertiary general hospitals in China., PMID:40421289
Predictors of drug survival of biologics in hidradenitis suppurativa: A systematic review and meta-analysis., PMID:40419221
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials., PMID:40418343
The position of anti-Tumor Necrosis Factor agents for the treatment of adult patients with Crohn's disease., PMID:40418234
Association of the TNFRSF1B-rs1061622 variant with nonresponse to infliximab in ulcerative colitis., PMID:40414945
Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes "Infliximab trough levels variability in inflammatory bowel disease"., PMID:40414284
A 30-year experience in neuro-Behçet disease., PMID:40414042
Skin lesions and chest pain in a patient with Crohn's disease., PMID:40413034
Case report: Spontaneous splenic rupture concomitant with serum sickness induced by infliximab., PMID:40410001
Network Meta-Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis., PMID:40407729
Ustekinumab in the Treatment of Crohn's Disease-A Narrative Review on Clinical Efficacy and Safety Profile., PMID:40407511
Effects of infliximab infusion on clinical symptom scores and serum cytokines in patients with inflammatory bowel disease., PMID:40400059
The Incidence and Management of TNF-α Inhibitor Induced Paradoxical Psoriasis in Children With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis., PMID:40400050
PErsistence and safety of subcutaneous infliximab 1 year after switch from intravenous route in IBD patients in REMission., PMID:40398832
Immunomodulatory Therapy Discontinuation for Reasons Other Than Efficacy in the Treatment of Ocular Inflammation., PMID:40397798
Long-Term Response Durability of Infliximab for Pediatric Inflammatory Bowel Disease in Japan: A Single Center Experience., PMID:40396153
For research use only. Not for human or drug use.
